Deruxtecan
Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan and Patritumab deruxtecan (HY-P99813)[2].
Product Specifications
CAS Number
1599440-13-7
Product Name Alternative
MC-GGFG-DXD
UNSPSC
12352203
Hazard Statement
H302, H315, H319, H335
Target
Drug-Linker Conjugates for ADC
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Deruxtecan_analog.html
Purity
99.94
Solubility
DMSO : 73.33 mg/mL (ultrasonic)
Smiles
O=C(C=CC1=O)N1CCCCCC(NCC(NCC(N[C@@H](CC2=CC=CC=C2)C(NCC(NCOCC(N[C@@H]3C4=C5C(C(N6C5)=CC([C@](O)(C(OC7)=O)CC)=C7C6=O)=NC8=CC(F)=C(C)C(CC3)=C48)=O)=O)=O)=O)=O)=O
Molecular Formula
C52H56FN9O13
Molecular Weight
1034.05
Precautions
H302, H315, H319, H335
References & Citations
[1]NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.|[2]Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107 (7) :1039-46.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
ADC Related
Clinical Information
Phase 4
Isoform
Camptothecins
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNUB3308-500 1x 500 µL
Napsin A (Lung Adenocarcinoma Marker) (NAPSA/3308), 0.2mg/mL
Sign In for Pricing
View Details 
